B H E Jansen1,2,3, G W Disselhorst1,2, T Schutte1,2, B Jansen4, R Rissmann5, M C Richir1,2, C J P W Keijsers6, F H M Vanmolkot7, A Maassen van den Brink8, C Kramers9, A M Vondeling10, G J H Dumont11, I de Waard-Siebinga12, M A Van Agtmael1,2, J Tichelaar1,2. 1. Department of Internal Medicine, Section Pharmacotherapy, VU University Medical Center, Amsterdam. 2. RECIPE (Research & Expertise Center In Pharmacotherapy Education), Amsterdam. 3. Department of Urology, VU University Medical Center, Amsterdam. 4. Department of General Practice & Elderly Care Medicine, VU University Medical Center, Amsterdam. 5. Centre for Human Drug Research, Leiden & Leiden University Medical Center. 6. Department of Geriatrics, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch. 7. Department of Internal Medicine, Maastricht UMC. 8. Department of Internal Medicine, Division of Pharmacology, Vascular and Metabolic Diseases, Erasmus MC, Rotterdam. 9. Department of Pharmacology-Toxicology, Radboud MC, Nijmegen. 10. Department of Geriatrics, Division of Internal Medicine and Dermatology, UMC, Utrecht. 11. Academic Medical Center, Amsterdam. 12. Faculty of Medicine, Division Pharmacology, University of Groningen.
Abstract
AIMS: Prescribing is a core skill for junior doctors, yet 8-10% of their prescriptions contain errors. To ensure adequate training in prescribing, it is important to define the diseases for which junior doctors should be competent to prescribe. The aim of the present study was therefore to identify the essential diseases in prescribing for junior doctors. METHODS: A two-round Delphi consensus study was conducted among medical specialists, general practitioners, junior doctors, pharmacists and pharmacotherapy teachers from all eight academic hospitals in the Netherlands. Using a five-point Likert scale, the participants indicated for each item on an initial questionnaire whether it should be considered an essential disease for junior doctors. The items for which ≥80% of all respondents agreed or strongly agreed were accepted as essential diseases. RESULTS: Sixty-two participants completed the Delphi survey. In total, 63 of 220 items were considered to be essential diseases. CONCLUSION: This is the first Delphi consensus study identifying exact conditions that junior doctors must be able to prescribe for. The essential diseases can be used for training in prescribing and assessment of junior doctors' prescribing competence.
AIMS: Prescribing is a core skill for junior doctors, yet 8-10% of their prescriptions contain errors. To ensure adequate training in prescribing, it is important to define the diseases for which junior doctors should be competent to prescribe. The aim of the present study was therefore to identify the essential diseases in prescribing for junior doctors. METHODS: A two-round Delphi consensus study was conducted among medical specialists, general practitioners, junior doctors, pharmacists and pharmacotherapy teachers from all eight academic hospitals in the Netherlands. Using a five-point Likert scale, the participants indicated for each item on an initial questionnaire whether it should be considered an essential disease for junior doctors. The items for which ≥80% of all respondents agreed or strongly agreed were accepted as essential diseases. RESULTS: Sixty-two participants completed the Delphi survey. In total, 63 of 220 items were considered to be essential diseases. CONCLUSION: This is the first Delphi consensus study identifying exact conditions that junior doctors must be able to prescribe for. The essential diseases can be used for training in prescribing and assessment of junior doctors' prescribing competence.
Authors: Donald Birkett; Kim Brøsen; Ingolf Cascorbi; Lars L Gustafsson; Simon Maxwell; Lembit Rago; Michael Rawlins; Marcus Reidenberg; Folke Sjöqvist; Tony Smith; Petra Thuerman; Andrew Walubo; Michael Orme; Folke Sjöqvist Journal: Basic Clin Pharmacol Toxicol Date: 2010-07 Impact factor: 4.080
Authors: Robert J van Unen; Jelle Tichelaar; Prabath W B Nanayakkara; Michiel A van Agtmael; Milan C Richir; Theo P G M de Vries Journal: J Clin Pharmacol Date: 2015-07-29 Impact factor: 3.126
Authors: T P G M De Vries; J M A Daniels; C W Mulder; O A Groot; L Wewerinke; K I Barnes; H A Bakathir; N A G M Hassan; L Van Bortel; M Kriska; B Santoso; E J Sanz; M Thomas; L E Ziganshina; P D Bezemer; C Van Kan; M C Richir; H V Hogerzeil Journal: Eur J Clin Pharmacol Date: 2008-06 Impact factor: 2.953
Authors: B H E Jansen; G W Disselhorst; T Schutte; B Jansen; R Rissmann; M C Richir; C J P W Keijsers; F H M Vanmolkot; A Maassen van den Brink; C Kramers; A M Vondeling; G J H Dumont; I de Waard-Siebinga; M A Van Agtmael; J Tichelaar Journal: Br J Clin Pharmacol Date: 2018-09-06 Impact factor: 4.335
Authors: Michiel J Bakkum; Jelle Tichelaar; Anne Wellink; Milan C Richir; Michiel A van Agtmael Journal: Clin Pharmacol Ther Date: 2019-07-29 Impact factor: 6.875
Authors: Erik Donker; David Brinkman; Milan Richir; Paraskevi Papaioannidou; Robert Likic; Emilio J Sanz; Thierry Christiaens; João Costa; Fabrizio De Ponti; Milo Gatti; Ylva Böttiger; Cornelis Kramers; Sarah Garner; Rahul Pandit; Michiel van Agtmael; Jelle Tichelaar Journal: BMJ Open Date: 2021-05-04 Impact factor: 2.692
Authors: Erik M Donker; David J Brinkman; Milan C Richir; Paraskevi Papaioannidou; Robert Likic; Emilio J Sanz; Thierry Christiaens; João N Costa; Fabrizio De Ponti; Ylva Böttiger; Cornelis Kramers; Michiel A van Agtmael; Jelle Tichelaar Journal: Eur J Clin Pharmacol Date: 2022-03-03 Impact factor: 2.953